C2N Diagnostics
Highly Engaged Employees
Business Services · Missouri, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
20 S Sarah St, Saint Louis, Missouri, 63...Phone Number
(877) 226-3424Website
www.c2ndiagnostics.comRevenue
$19.4 MillionIndustry
About C2N Diagnostics
C2N Diagnostics (www.c2ndiagnostics.com) was formed by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, MO and LifeTech Research, a technology research and venture development firm (www.lifetechresearch.com). C2N is commercializing a suite of biomarker tests to enable early detection of debilitating neurodegenerative disorders before symptom onset, facilitate drug discovery, and enhance clinical drug development at lower risk and cost. Besides its biomarker platform, C2N is also developing therapeutics for neurodegenerative disorders. In March 2015, C2N formed a global partnership with AbbVie to develop and commercialize a portfolio of anti-tau antibodies for the treatment of Alzheimer's Disease and other neurological disorders. AbbVie is currently conducting phase 2 trials with the lead candidate ABBV-8E12 in Alzheimer's disease and Progressive Supranuclear Palsy.Explore more
SIC Code 87,873NAICS Code 54,541Show moreC2N Diagnostics Org Chart
C2N Diagnostics Tech Stack
A closer look at the technologies used by C2N Diagnostics
Top Business Services Companies
See more top companies
Frequently Asked Questions Regarding C2N Diagnostics
Sign Up For FreeTo access detailed company insights
C2N Diagnostics (www.c2ndiagnostics.com) was formed by scientific co-founders Drs. David Holtzman and Randall Bateman of Washington University School of Medicine in St. Louis, MO and LifeTech Research, a technology research and venture development firm (www.lifetechresearch.com). C2N is commercializing a suite of biomarker tests to enable early det... Read More